PT - JOURNAL ARTICLE AU - Chaolin Li AU - Mianxin Liu AU - Jing Xia AU - Lang Mei AU - Qing Yang AU - Feng Shi AU - Han Zhang AU - Dinggang Shen TI - Predicting brain amyloid-β PET phenotypes with graph convolutional networks based on functional MRI and multi-level functional connectivity AID - 10.1101/2021.08.26.21262325 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.26.21262325 4099 - http://medrxiv.org/content/early/2021/08/29/2021.08.26.21262325.short 4100 - http://medrxiv.org/content/early/2021/08/29/2021.08.26.21262325.full AB - The detection of amyloid-β (Aβ) deposition in the brain provides crucial evidence in the clinical diagnosis of Alzheimer’s disease (AD). However, the efficiency of the current PET-based brain Aβ examination suffers from both coarse, visual inspection-based bi-class stratification and high scanning cost and risks. In this work, we explored the feasibility of using non-invasive functional magnetic resonance imaging (fMRI) to predict Aβ-PET phenotypes in the AD continuum with graph learning on brain networks. First, three whole-brain Aβ-PET phenotypes were identified through clustering and their association with clinical phenotypes were investigated. Second, both conventional and high-order functional connectivity (FC) networks were constructed using resting-state fMRI and the network topological architectures were learned with graph convolutional networks (GCNs) to predict such Aβ-PET phenotypes. The experiment of Aβ-PET phenotype prediction on 258 samples from the AD continuum showed that our algorithm achieved a high fMRI-to-PET prediction accuracy (78.8%). The results demonstrated the existence of distinguishable brain Aβ deposition phenotypes in the AD continuum and the feasibility of using artificial intelligence and non-invasive brain imaging technique to approximate PET-based evaluations. It can be a promising technique for high-throughput screening of AD with less costs and restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Guangzhou Science and Technology Plan Project (No. 202102010495), the ShanghaiTech Startup funds, and the National Key Scientific Instrument Development Program (No. 82027808). Han Zhang was supported by Shanghai Zhangjiang National Innovation Demonstration Zone Special Funds for Major Projects ("Human Brain Research Imaging Equipment Development and Demonstration Application Platform" (ZJ2018-ZD-012)).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the OASIS Brains project group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article. https://www.oasis-brains.org